biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sniper007on Mar 31, 2014 2:22pm

183 Views

Post# 22391269

RE:RE:Liolios Useless

And what pharma do you suppose the deal will be with Sir_Holler ??? Roche?? Nope, not now. Short term, the deal won't be on BT2111, BTI is moving forward with that on their own. Why would they give that up at this point in the game? And they don't need money right now but as you keep posting, licensing deals are imminent which means cash in pocket if results continue to be successful. Read Neinstein's post from last week, he's more on the right track.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario